218 related articles for article (PubMed ID: 30538068)
1. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
[TBL] [Abstract][Full Text] [Related]
2. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
3. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
[TBL] [Abstract][Full Text] [Related]
4. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.
Suarez-Sarmiento A; Nguyen KA; Syed JS; Nolte A; Ghabili K; Cheng M; Liu S; Chiang V; Kluger H; Hurwitz M; Shuch B
Clin Genitourin Cancer; 2019 Dec; 17(6):e1163-e1170. PubMed ID: 31519468
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
[TBL] [Abstract][Full Text] [Related]
8. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
10. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):845-853. PubMed ID: 29976497
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.
Wardak Z; Christie A; Bowman A; Stojadinovic S; Nedzi L; Barnett S; Patel T; Mickey B; Whitworth T; Hannan R; Brugarolas J; Timmerman R
Clin Genitourin Cancer; 2019 Apr; 17(2):e273-e280. PubMed ID: 30595522
[TBL] [Abstract][Full Text] [Related]
12. Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
Ruste V; Sunyach MP; Tanguy R; Jouanneau E; Schiffler C; Carbonnaux M; Moriceau G; Neidhardt EM; Boyle H; Robin S; Négrier S; Fléchon A
J Neurooncol; 2021 May; 153(1):133-141. PubMed ID: 33837880
[TBL] [Abstract][Full Text] [Related]
13. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
Vogl UM; Bojic M; Lamm W; Frischer JM; Pichelmayer O; Kramer G; Haitel A; Kitz K; Harmankaya K; Zielinski CC; Schmidinger M
BMC Cancer; 2010 Sep; 10():480. PubMed ID: 20819239
[TBL] [Abstract][Full Text] [Related]
14. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
16. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.
Sun M; De Velasco G; Brastianos PK; Aizer AA; Martin A; Moreira R; Nguyen PL; Trinh QD; Choueiri TK
Eur Urol Focus; 2019 May; 5(3):474-481. PubMed ID: 29311016
[TBL] [Abstract][Full Text] [Related]
17. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
[TBL] [Abstract][Full Text] [Related]
19. Brain metastasis from renal cell carcinoma.
Bennani O; Derrey S; Langlois O; Castel H; Laquerriere A; Freger P; Proust F
Neurochirurgie; 2014; 60(1-2):12-6. PubMed ID: 24636403
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
